SHINE plans new isotope production facility in the Netherlands

May 24, 2021, 7:00AMNuclear News
A rendering of the SHINE medical isotope production facility planned for construction in Veendam, the Netherlands. (Image: Shine)

SHINE Medical Technologies plans to locate its European medical isotope production facility in the Netherlands after a yearlong search and a review of more than 50 proposals from sites across Europe. The company announced on May 20 that construction at the site should begin in 2023 with commercial production starting in late 2025.

SHINE allowed more flexibility in procuring production components

May 18, 2021, 9:29AMNuclear News
SHINE executives, construction managers, and partners commemorate a construction milestone of the medical isotope production facility in March. (Photo: SHINE)

The Nuclear Regulatory Commission has approved a request by SHINE Medical Technologies for an exemption from regulations on how commercial grade equipment is defined, allowing the company to more easily procure components for the medical isotope production facility it is building in Janesville, Wis.

Accelerators delivered to NorthStar medical isotope facility

April 27, 2021, 7:00AMANS Nuclear Cafe
NorthStar is capable of producing Mo-99 using non-uranium-based processes. Photo: NorthStar Medical Radioisotopes

Completing a 5,700-mile journey from Belgium, two 24-ton particle accelerators were delivered to NorthStar Medical Radioisotopes’ facility in Beloit, Wis., on April 22, the Wisconsin State Journal reported. Photos and a video of the accelerators being received at the facility are included in the report.

Progress being made toward Mo-99 production at Darlington

September 29, 2020, 12:25PMNuclear News

Darlington nuclear generating station. Photo: OPG

Ontario Power Generation, its subsidiary Laurentis Energy Partners, and BWXT ITG Canada and its affiliates announced on September 24 that the companies are making “significant progress” toward the production of molybdenum-99 at OPG’s Darlington nuclear power plant. Darlington will become the first commercial operating nuclear reactor to produce the medical radioisotope.

A precursor to technetium-99m, Mo-99 is used in more than 40 million procedures a year to detect cancers and diagnose various medical conditions.

NRC expected to issue Mo-99 facility license for Shine in 2021

May 13, 2020, 9:10PMNuclear News

Shine Medical Technologies, which is building a medical isotope production facility in Janesville, Wis., said on May 11 that it expects to have an operating license issued by the Nuclear Regulatory Commission by October 2021. Shine’s application seeking approval to operate the facility, which will produce isotopes including molybdenum-99, was accepted and docketed by the NRC last October. Mo-99, the precursor to technetium-99m, is used in more than 40 million medical patient procedures every year.

IRE produces first batch of LEU-based Mo-99

May 6, 2020, 8:51AMNuclear News

Belgium’s National Institute of Radioelements (IRE) announced on April 30 that it has produced its first batch of commercial molybdenum-99 from low-enriched uranium (LEU) targets. The first batch of Mo-99, whose decay product, technetium-99m, is used in nuclear medicine for diagnostic imaging, was produced for the U.S. health market. IRE said that the conversion to LEU represents a key milestone for the institute in the global commitment to end the civilian use of highly enriched uranium (HEU) for the production of Mo-99.

Mo-99 supply put at risk by COVID-19 pandemic

April 7, 2020, 10:18AMNuclear News

The U.S. healthcare industry is warning that the COVID-19 pandemic may threaten supplies of the medical radioisotope molybdenum-99, whose decay product, technetium-99m, is considered the workhorse isotope in nuclear medicine for diagnostic imaging. The online magazine Radiology Business recently reported that the American Society of Nuclear Cardiology (ASNC) alerted its members on April 1 that it is monitoring supply shortages of Mo-99 “more closely than ever” during the pandemic.